Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.68 |
| ▸ | AXL | P30530 | 6/20 | 0.68 |
| ▸ | MERTK | Q12866 | 4/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 7/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480344 | 0.90 | KDR (0.57) | METAXLMERTKKDRABL1 | |
| SCHEMBL2476315 | 0.88 | MET (0.70) | METAXLMERTKPDGFRAKIT | |
| SCHEMBL27366034 | 0.83 | MET (0.62) | METAXLMERTKABL1TYRO3 | |
| SCHEMBL16089993 | 0.81 | MET (1.00) | METAXL | |
| SCHEMBL16089992 | 0.81 | MET (1.00) | METAXLMERTK | |
| SCHEMBL5202980 | 0.81 | KDR (0.85) | METPDGFRAKITKDRCSF1R | |
| SCHEMBL24196303 | 0.81 | MERTK (0.64) | METAXLMERTKABL1TYRO3 | |
| SCHEMBL30381010 | 0.81 | MERTK (0.64) | METAXLMERTKABL1TYRO3 | |
| SCHEMBL29764949 | 0.80 | AXL (0.62) | METAXLMERTKKITKDR | |
| SCHEMBL23147550 | 0.80 | AXL (0.62) | METAXLMERTKKITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023926-B1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer Pharma AG (DE) | 2011-10-12 | — | — | EP | disclosed |
| EP-2023926-B1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer Pharma AG (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2023926-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer HealthCare AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008048375-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048375-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | MKI67, FLT4, VEGFA | MET 553/4885AXL 1154/4885MERTK 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.